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Abstract: Advanced-stage follicular lymphoma (FL) is generally considered incurable with
conventional systemic therapies, but historic series describe long-term disease-free survival in stage
III disease treated with wide-field radiation therapy (WFRT), encompassing all known disease sites.
We report outcomes for patients staged with 18F-fluorodeoxyglucose positron emission tomography
(FDG-PET) and treated with CT-planned WFRT, given as either comprehensive lymphatic irradiation
(CLI) or total nodal irradiation (TNI). This analysis of a prospective cohort includes PET-staged
patients given curative-intent WFRT as a component of initial therapy, or as sole treatment for stage
III FL. Thirty-three PET-staged patients with stage III FL received WFRT to 24–30Gy between 1999
and 2017. Fifteen patients also received planned systemic therapy (containing rituximab in 11 cases)
as part of their primary treatment. At 10 years, overall survival and freedom from progression
(FFP) were 100% and 75%, respectively. None of the 11 rituximab-treated patients have relapsed.
Nine relapses occurred; seven patients required treatment, and all responded to salvage therapies.
A single death occurred at 16 years. The principal acute toxicity was transient hematologic; one
patient had residual grade two toxicity at one year. With FDG-PET staging, most patients with stage
III FL experience prolonged FFP after WFRT, especially when combined with rituximab.
Keywords: follicular lymphoma; radiation therapy; chemotherapy; rituximab
1. Introduction
Follicular lymphoma (FL) is a common mature B-cell malignancy, characterised by a long
natural history, remarkable sensitivity to radiation therapy (RT) [1] and high response rates to
immunochemotherapy [2]. Grade 3B follicular lymphoma is biologically akin to the aggressive diffuse
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large B-cell lymphoma [3] and is managed accordingly. All other histologic grades of FL are known to
be potentially curable by RT [4–6] or RT plus chemo-immunotherapy, when limited to stages I and
II [7,8]. Stage III FL, where disease is confined to nodal sites on both sides of the diaphragm, but
without bone marrow or visceral involvement, is typically grouped with stage IV in the “advanced
disease” category in current management paradigms and in modern clinical trials [9,10]. Advanced FL
is widely considered to be incurable with any current therapy, except allogeneic hematopoietic stem
cell transplantation, which is applicable in an extremely small proportion of patients [11]. Complete
remission is usually achieved following induction therapy with immuno-chemotherapy [12–14]
and progression-free survival can be improved by maintenance CD20-antibody, rituximab [15] or
obinutuzumab [16]. In selected patients, durable remissions can be attained with high dose systemic
therapy and hematopoietic stem cell transplantation [17,18] but it is unclear whether this approach is
curative [19]. Despite initial excellent responses, most patients with advanced FL eventually experience
relapse [20]. Subsequent remissions can often be attained with further systemic therapies, but these are
typically of progressively shorter durations and lymphoma is the most common cause of death [21].
Before effective systemic therapy became available, RT was the most widely used therapeutic
modality for indolent lymphomas. For patients with stage III FL, the achievement of long term
disease-free survival has been consistently reported in a proportion of patients after wide-field RT
(WFRT) to nodal groups above and below the diaphragm, either as a single modality [22–26], combined
with chemotherapy [27], or following relapse after chemotherapy [28]. In a historic series from
Stanford [24,26], MD Anderson Cancer Center [29], Wisconsin [23], Florida [22,30] and a more recent
series from Wurzburg [25], a substantial proportion of patients with stage III FL have consistently
attained long-term progression-free survival (PFS) and were apparently cured after WFRT. Barriers to
the more widespread utilisation of such WFRT approaches include the inability to confidently exclude
low volume or focal marrow disease, imprecision and low sensitivity for the detection of small
nodal or other extra-medullary sites of disease involvement below the detection limit of CT scanning,
and concerns regarding the potential late toxicities of higher dose large field RT. Ensuring adequate
sampling and rigorous pathological scrutiny, including immuno-histochemistry, of multiple levels
have enhanced the detection of low level marrow disease [31] and modern PET-CT has enhanced
systemic disease detection [32–34].
With the advent of effective (albeit non-curative) systemic therapy regimens, and due to toxicity
concerns and technical complexity, WFRT approaches have largely been superseded by systemic
therapy or by “watchful waiting” [35] as initial management strategies for patients with stage III FL.
Our multidisciplinary group has continued to offer curative–intent WFRT to patients with rigorously
staged IIIA FL, who met predefined eligibility criteria. When 18F-fluorodeoxyglucose positron emission
tomography (FDG-PET) became available at our centre, it was routinely used for staging patients with
FL, along with bone marrow biopsy. PET frequently upstages apparently localized FL to advanced
disease [32], and by identifying patients with disease that is too extensive for potentially curative RT,
patient selection, and thereby the results of RT, can be improved. In this paper, we report disease
control and toxicities for patients with stage III FL treated with curative-intent WFRT in the PET era.
2. Results
Between July 1999 and December 2017, 36 patients commenced WFRT in the form of either
comprehensive lymphatic irradiation (CLI, n = 30) or total nodal irradiation (TNI, n = 3), for stage III
follicular lymphoma. CLI and TNI are described in the methods section. Two patients were ineligible
for analysis, because the RT was delivered for management of relapsed disease after prior therapy (RT
and chemotherapy respectively) and a third patient did not have a pre-treatment PET scan, leaving 33
eligible patients. The demographics of these 33 analysed patients are shown in Table 1. The median
age was 50 years and 17 (51%) were female. All patients had at least one FDG-avid site of disease on
PET imaging. The maximum number of Ann Arbor sites involved by lymphoma was eight and the
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largest tumour diameter was 8.5 cm. The follicular lymphoma international prognostic index (FLIPI)
scores were 1 n = 18, 2 n = 14 and 3 n = 1.
Table 1. Demographic data.
Variable Result
Age
Mean (SD) 50 (9)
Median (range) 49 (2–71)
Interquartile range 44–56
Histological grade
1–2 32 (97%)
3a 1 (3%)
Number of involved Ann Arbor Sites
2 7 (21%)
3 6 (18%)
4 9 (27%)
5 7 (21%)
≥6 4 (12%)
Prescribed RT dose
24Gy 4 (12%)
30Gy 29 (88%)
Maximum nodal diameter (cm)
Mean (SD) 3 (2)
Median (range) 2.5 (1–8.5)
Interquartile range 2–3
Maximum diameter
≤5 cm 28 (85%)
>5 cm 5 (15%)
Treatment
RT alone 18 (55%)
RT + systemic therapy 15 (45%)
Rituximab
No Rituximab 22 (67%)
Rituximab 11 (33%)
Because of concerns that future intensive chemotherapy may not be deliverable due to marrow
toxicity if an early relapse occurred after RT, initially all patients were routinely offered pre-emptive
peripheral blood hematopoietic stem cell harvesting, with G-CSF, and often cyclophosphamide for
mobilisation, and several patients also received rituximab for the putative purging of potential
sub-clinical diseases at this time [36]. An ongoing evaluation revealed that stored stem cells had not
been used, so this practice was ceased after 23 patients had been harvested. Table 2 illustrates the
regimens used for harvesting stem cells. In seven cases, rituximab was given at the time of stem cell
harvesting. In addition to TNI or CLI, 15 patients (45%) received additional systemic therapy, either as
adjuvant treatment or as part of the stem cell harvesting process. Five patients had multiagent systemic
therapy, either before, or both before and after, RT, as part of a planned combined modality approach.
Three further patients had single agent rituximab (up to four cycles), either before or after RT.
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Table 2. Systemic therapies with potential anti-lymphoma effects given as a component of primary
treatment or at time of stem cell harvesting. Patients receiving any anti-lymphoma systemic therapy:
n = 15 (all shaded cells). Patients receiving any rituximab: n = 11 (yellow shaded cells only).
Patient
ID Number
Stem Cell
Harvest Mobilization
Stem Cell
Harvest Purge
Systemic Therapy
Pre-RT
Systemic Therapy
Post RT
Patient Cyclophosphamide1.5 g/m2 Rituximab
1 Yes No
2 Yes No
3 Yes No R-CHOP × 6
4 No No CVP × 6
5 Yes Yes Rituximab × 4
6 Yes Yes
7 Yes Yes
8 Yes No
9 Yes Yes
10 No No R-CVP × 2 R-CVP × 3
11 No Yes Rituximab
12 No Yes
13 No Yes
14 No No R-CHOP × 3
15 No Yes Rituximab × 4
Abbreviations: R-CVP = rituximab, cyclophosphamide, vincristine, prednisolone, R-CHOP = rituximab,
cyclophosphamide, doxorubicin, vincristine, prednisolone, ID = identification.
After a response assessment with PET and/or CT imaging, patients were generally reviewed at
three-monthly intervals for two years, six-monthly until five years and annually thereafter. Four patients
were lost to follow up for geographic reasons (n = 3), or because of psychiatric disorder (n = 1).
Long-term survivors were monitored for relapse, development of any second malignancy and potential
late toxicities.
2.1. Radiation Therapy Delivery and Acute Toxicity
Thirty-two (97%) patients completed the prescribed radiotherapy course. There was one patient (later
diagnosed with idiopathic thrombocytopenic purpura) who ceased abdominal RT due to thrombocytopenia
at 21Gy. Non-hematologic acute toxicities of RT > grade 1 were all grade 2: nausea/vomiting (n = 4),
diarrhoea (n = 3), xerostomia (n = 7), mucositis/esophagitis (n = 7), skin (n = 3), proctitis (n = 1).
The hematologic toxicities are summarized in Table 3. All patients had at least grade 1 hematologic
toxicity. The major hematologic consequence of RT was thrombocytopenia, causing interruptions
in RT in three cases, including the above patient, who prematurely ceased abdominal RT. Although
lymphopenia occurred in all patients and moderate neutropenia was seen in the majority, only one
significant infective episode occurred during treatment (dermatomal herpes zoster). A single
haemorrhagic event occurred; bleeding from haemorrhoids.
Table 3. Hematologic toxicity of radiation therapy. G-CSF = granulocyte colony-stimulating factor.
Toxicity Hemoglobin Platelets Neutrophils
Nadir blood count
Median Range
10.6 g/dL
(7.4–13.8)
46
(11–238)
0.87
(0.3–3.17)
Patients with
any toxicity ≥3 2/33 (6%) 16/33 (48%) 17/33 (52%)
Duration Gd ≥3 toxicity
Median Range
4 days
(1–8)
13 days
(7–115)
12 days
(1–44)
Hematological
Support given
5/33 (15%)
Red cell transfusion
1/33 (3%)
Platelet transfusion
5/33 (15%)
(G-CSF injection)
Residual Toxicity after 1y 3/33 Grade 1 3/33 grade11/33 grade 2 * 0
* This patient had idiopathic Thrombocytopenic Purpura.
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2.2. PET Response Assessment
Thirty patients had FDG-PET for response assessment, and all (100%) showed a complete metabolic
response (CMR). These assessments pre-dated the adoption of the Deauville scale [37], and would
be consistent with the Deauville responses of 1–2. In two cases, PET response was assessed after
neoadjuvant systemic therapy, before RT. An example of PET response assessment is shown in Figure 1.
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2.3. Overall Survival and Freedom from Progression
Individual patient outcomes are shown in the event history chart (Figure 2). The study close-out
date was April 11th, 2018. Median follow up was nine (range 0.5–18.5) years. OS was 100% at
10 years and only one patient has died (in long-term remission after PBSCT aged 82). Freedom from
progression (FFP) (Figure 3) for the entire cohort was 79% at 5 years (95% confidence interval 65–96)
and 75% at 10 years (95% CI 60–93%). The factors potentially associated with FFP are shown in Table 4.
The delivery of any systemic therapy (p = 0.002, Figure 4) or any rituximab (p = 0.025, Figure 5) was
associated with superior FFP. No rituximab-treated patient had yet had a progressive disease and only
one patient treated with systemic therapy without rituximab had progressed. Patients with a FLIPI
score of 1 had fewer progressions than those with a score > 1 (HR 3.41, CI 0.84–13.76, p = 0.086).
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Table 4. Univariable analysis for Freedom-From Progression (FFP).
Variable Level Number of Cases 5 years FFP (95% CI) HR (95% CI) p-Value
Any systemic therapy No 18 57% (36–91) 1 0.002Yes 15 100% 0.1 (0.01–0.5)
Any Rituximab No 22 67% (48–93) 1 0.025Yes 11 100% Not estimable
Maximum tumour diameter
≤5 cm 28 82% (68–100) 1
0.057
>5 cm 5 60% (29–100) 4.8 (1.1–21.6)
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2.4. Management after Progression
By the last follow-up, nine patients had manifest disease progression. In two cases, multifocal
low volume relapse was managed expectantly. In two cases, with isolated relapses in the orbit and
peri-renal areas respectively, CMR was attained with salvage local RT. The latter patient later relapsed
with DLBCL, and after R-CHOP induction, underwent peripheral blood stem cell transplantation
(PBSCT) and was in remission at last follow up > 4 years later. Two further patents had transformation
to DLBCL at first relapse and were treated with salvage R-CHOP and PBSCT. Both attained sustained
complete responses and one of these died without relapse. The remaining three patients all had
multifocal relapses and received salvage immunochemotherapy (FCR n = 2, R-CHOP n = 1). In all
cases, salvage chemoimmunotherapy was completed on schedule, with no more than the expected
haematological toxicity, and in all cases CMR was attained.
2.5. Subacute and Late Toxicities of Radiation Therapy
Two patients had significant radiation pneumonitis of grade 2 and 4 respectively, after completion
of RT. Both recovered fully, although one patient required hospital admission, and both required
steroids. One patient developed renal artery stenosis at five years, within the RT field, but of
uncertain relation to therapy. One patient had treatment-related bilateral avascular necrosis of the
hips, requiring total hip replacements. One patient developed severe fatigue and depression after
therapy and another had an anxiety disorder. One patient developed shingles after RT and two
developed hypothyroidism, requiring replacement therapy. None of the patients developed any
clinically significant renal parenchymal dysfunctions.
2.6. Second Malignancies
Five new neoplasms were diagnosed after the commencement of RT. One case each of prostate
cancer (metastatic to bone), mature teratoma of the testis, melanoma of the forearm and squamous
carcinoma of the scalp occurred, all outside the RT fields. One case of follicular thyroid cancer occurred
within the RT field, and was successfully treated with resection. There were no cases of leukemia
or myelodysplasia.
3. Discussion
PET-staged patients with stage III FL, treated with CT-planned WFRT, experienced exceptional
long-term overall survival in this report. The majority of patients were free from relapse at 10 years,
and in the small subset of patients who received any rituximab in addition to WFRT, no relapses had
been observed at last follow up. No lymphoma-related deaths were recorded and only one death
occurred from unrelated causes. These results not only confirm the existing, but infrequently cited,
literature showing long-term disease control with WFRT in stage III FL, but they surpass the outcomes
reported in those historic reports. As in earlier series, very prolonged survival without relapse could
be considered consistent with “cure” in cases, where patients in long-term remission survive to normal
life expectancy.
The favourable long-term outcomes reported in this series are attributable to several factors,
including careful patient selection, PET scanning excluding patients with occult systemic disease or
who were too advanced for treatment with RT, and the incorporation of PET and CT information into
RT planning, ensuring that any geographic miss of gross disease was avoided. PET also directed the
biopsy of lesions with high standardized-uptake values to exclude aggressive lymphoma. The frequent
addition of systemic therapy in this series, especially rituximab in combination with RT, was associated
with a remarkably low relapse rate, consistent with “spatial cooperation”, where gross disease is
controlled by RT and occult disease controlled by systemic therapy. These results are consistent with
the randomized phase III TROG 99.03 [7] and the prospective phase II MIR trial [38] in stage I-II FL,
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in which the combination of RT to all sites of gross disease with rituximab-containing systemic therapy
was associated with very high rates of durable complete remission.
A 100% rate of CMR on post-treatment PET scanning was expected, given the known very high
radiosensitivity of FL. Although RT has long been considered an exclusively local therapy, there is
emerging evidence that in FL, local RT may be associated with the regression of distant disease in the
absence of other treatment (MacManus MP et al., in press). The so-called “abscopal” effect of RT may
be more common in FL than previously known and is considered to be an immunologically mediated
phenomenon. The effectiveness of the combination of local RT and anti-CD20 antibody therapy in
the TROG 99.03 and MIR trials in early stage FL may be derived from an interaction between RT,
immunotherapy and the host immune system. Such an interaction is also plausible, but unproven,
in the stage III setting. Because isolated local treatment failure is unusual with RT alone, it is unlikely
that the efficacy of RT combined with rituximab is due to a local radiosensitizing effect.
WFRT has largely been abandoned in stage III FL, because of its technical complexity, concerns
about toxicity and the increasing effectiveness of systemic therapies, especially immuno-chemotherapies
including anti-CD20 antibodies. Another concern is that salvage systemic therapy might not be
deliverable after WFRT due to myelotoxicity, especially for relapses in the first year after treatment.
Reassuringly, in our series, the relapse rate was very low and those patients who required systemic
therapy for relapse, including those treated aggressively for transformation to aggressive lymphoma,
were able to receive full dose chemotherapy without delays due to myelotoxicity, and even subsequent
successful stem cell harvesting.
The results reported here suggest that WFRT should at least be considered as a viable treatment
option for selected patients with stage III, especially those who wish to pursue a “curative” intent
therapeutic approach and those who refuse chemotherapy. The ideal candidate patients would have
an extent of disease that would be readily treatable within the standard TNI or CLI volumes and would
have a life expectancy exceeding 10–15 years in the absence of lymphoma. The long natural history
of FL means that a prolonged “lead time” would be required before any potential survival benefit of
long-term disease control could be realised by patients, given the excellent short and medium term PFS
results that are attainable with modern systemic therapies. Patients treated with WFRT must undergo
several months of daily treatment for a potential future benefit, when they could, in some cases,
undergo initial management with “watchful waiting”, or proceed directly to immuno-chemotherapy.
To effectively compare RT or RT plus anti-CD20 antibody therapy with current management approaches
would require a prohibitively large randomized controlled trial with prolonged (> 10 years) follow up.
Short-term results would be expected to be similar, even if there was a late benefit from RT.
In this series, hematologic toxicity was almost universal during the final phase of treatment
and was prolonged in a few cases, especially thrombocytopenia. Nevertheless, by one year, blood
counts were normal in virtually all patients. There were no significant bleeding events or bacterial
infections during RT and only one significant viral infection (herpes zoster). Salvage therapies were
delivered without unusual myelotoxicity in those few patients who relapsed. Prophylactic storage
of hematopoietic stem cells proved unnecessary, because no autologous stem cell transplants were
performed using these products, as the few transformation events seen were quite late (all >4 years after
RT) and stem cells were successfully harvested in those few patients at that time. Acute toxicities other
than myelosuppression included fatigue and diarrhoea, responsive to loperamide or similar agents.
Nausea was largely prevented by the prophylactic use of ondansetron. Although short-term RT-related
toxicities may be greater than would be expected with some first-line systemic therapies, systemic
therapies are not without toxicity, and with each relapse, cumulative toxicities increase. Over the
lifetime of the patient, the toxicity of wide WFRT may actually be significantly less for many patients
than the cumulative toxicities of sequential systemic therapies, if RT is able to provide durable disease
control. However, in the absence of randomized trials, it cannot be known that the favourable outcomes
that we report here could not have been achieved with systemic therapy in a similarly selected cohort
of stage III FL patients. At present, the literature contains little information on outcomes for stage III
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FL treated with modern systemic therapy regimens, because these cases are reported combined with
stage IV patients in the “advanced” disease category.
The therapeutic approach reported here may not represent the optimum way to utilise RT in stage
III FL. There has been a long-established trend towards eliminating the use of RT in a wide range
of clinical scenarios in lymphoma, to prevent late toxicities. In those diseases where RT is still used,
such as in early stage FL, RT is now given in lower doses and to smaller volumes than in the past [5].
These approaches have minimized the potential for early and late effects of RT. The TROG 99.03 trial [7]
showed that in stage I-II FL, local RT could reliably eradicate local disease, and that systemic therapy
could control occult distant disease in a majority of cases, thereby achieving very favourable long-term
freedom-from relapse results. The combination of chemoimmunotherapy and local RT may also prove
to be effective in preventing relapse in stage III FL. Information from the FoRT [39] trial suggests that
24 Gy is a high enough dose in FL and that very low dose RT (4Gy in 2 fractions) can control local
disease without toxicity in a high proportion of cases. An alternative approach to combining RT and
chemoimmunotherapy in FL stage III might involve the addition of very low dose involved-site RT to
all lymphoma lesions visualized on PET. Despite the increasing efficacy of modern systemic therapies
in advanced FL, not all patients achieve complete remissions, and many patients who do experience
remission will relapse at initially involved sites of disease. A modern combined modality approach in
stage III, with optimum systemic therapy and smaller volume, low dose conformal RT may have the
potential to improve outcomes in FL with little, if any, increase in toxicity.
4. Materials and Methods
This study was carried out following the rules of the Declaration of Helsinki of 1975
(https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/), revised in 2013. Patient
data for this Peter MacCallum Cancer Centre ethics-committee approved study (approval 18_87R)
were extracted from a prospective database established in 1999. Because this study reports an analysis
of de-identified data from a clinical database, individual patient consent was not required according
to institutional policy. Treatment details, therapeutic response information and follow-up data were
available. The completeness of the patient cohort was validated by cross-referencing the hospital
radiotherapy treatment database with a state-wide cancer registry, assuring complete ascertainment.
Laboratory data, including information on toxicities, and blood counts were extracted retrospectively
from hospital records. All potential treatment candidates were discussed at weekly multidisciplinary
meetings attended by hematologists, radiation oncologists, imaging specialists and members of other
relevant disciplines. Patients with an anticipated life expectancy of >10–15 years independent of their
FL were offered WFRT as one of a range of available management options, that could include watchful
waiting or immediate systemic therapy.
Patients were informed that RT was the only therapeutic option known at the time to be associated
with a significant potential for cure. Although RT alone was the preferred option of the multidisciplinary
group overall, some hematologists in our group preferred to combine WFRT with systemic therapy.
All PET-stage III patients treated with wide field RT or RT plus systemic therapy are included in
this report.
4.1. Inclusion Criteria
Follicular lymphoma grade I–IIIa; bone marrow aspirate and trephine without morphological
evidence of involvement by lymphoma, after comprehensive examination of adequate sampling
(at least 3 levels of a 20 mm or greater length trephine core); stage III disease after FDG-PET staging;
prescribed treatment with curative intent WFRT in the form of CLI or TNI as defined below; treatment
commenced between July 1999 and December 2017.
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4.2. Exclusion Criteria
WFRT given as salvage for relapsed disease; FDG-PET staging not performed; bulk > 10 cm;
disease distribution, including sites more peripheral than axillae or groins (e.g., epitrochlear, popliteal).
4.3. PET Imaging
Before 2002, patients underwent FDG-PET scans on a GE Quest 300-H scanner, (UGM Medical
Systems Inc., Philadelphia, PA, USA) and separately acquired CT scans. From 2002, patients underwent
imaging on a combined Discovery LS PET/CT scanner (GE Medical Systems Milwaukee, WI) and
subsequently on Siemens Biograph 64, GE Discovery 690 or GE Discovery 710 PET/CT systems.
Standardized whole body image acquisition protocols were used and scans were read qualitatively.
Patients with accessible highly FDG-avid lesions (SUVmax > 15) underwent targeted biopsies to exclude
transformation to aggressive lymphoma. FDG-PET information was routinely used for radiotherapy
planning, ensuring that all FDG-avid sites received at least 24–30Gy. PET imaging was also routinely
performed after the completion of RT, to assess response using visual criteria [40,41].
4.4. Radiotherapy
Radiotherapy was delivered sequentially to supra-diaphragmatic volumes, with a minimum gap
of four weeks to permit hematological recovery. The most symptomatic or largest region was treated
first. In all cases, the supradiaphragmantic RT approach was similar. The infradiaphragmatic RT
approach depended on the presence (CLI) or absence (TNI) of mesenteric disease, as described below.
Treatment was CT-planned, with neck immobilization in a cast, and delivered in daily fractions on
a linear accelerator using 6 or 18 MV photon beams. In the most recent case, intensity modulated
radiation therapy (IMRT) was used. All non-bulky sites of gross disease were prescribed 24–30Gy
and sites > 5cm in maximum transverse diameter were boosted to 36Gy. Wide-field RT was given in
1.5Gy fractions.
4.5. Supradiapragmatic RT
“Mantle” treatment volumes [42] matched the upper borders of the infradiaphragmatic volumes at
the level of the top of the diaphragm. The lateral borders of each AP/PA mantle field covered the axillae.
Mediastinal, hilar, infraclavicular, axillary and low-neck nodes were all included. The upper border of
the mantle field was matched to the lateral opposed “Waldeyer’s” fields that covered the upper neck
nodes, tonsils and nasopharynx. The mantle field was treated to 24–30 Gy, but the Waldeyer’s field
was treated to 20–24 Gy if no disease was apparent.
4.6. Infradiaphragmatic RT
Abdominal and pelvic RT was delivered, entirely or partially, via anterior and posterior opposed
fields at extended focus to skin distance (FSD). If mesenteric nodes were involved, whole abdominal
and pelvic RT was delivered (CLI), often including a component from lateral fields, shaped to avoid
kidneys. If mesenteric nodes were negative, an inverted-Y [42] and spleen volume were treated (TNI,
example shown in Figure 6). The infradiaphragmatic field extended from the top of the diaphragm
and inferiorly included the inguinal and femoral nodes, if involved, with shielding of the genitalia and
the base of the bladder. After an initial phase of treatment given to 24 Gy, areas of gross disease were
boosted to 30 Gy, if this could safely be accomplished. Posterior partial thickness kidney shielding
was used, restricting mean kidney doses to <15 Gy. The right lobe of the liver was shielded from
anterior and posterior fields after 18Gy, except in regions where gross disease would have been spared.
Daily anti-emetic therapy with oral ondansetron 8mg b.i.d. was given and full blood counts were
performed at least weekly during treatment.
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4.7. Statistical Considerations
The Kaplan–Meier method was used to estimate the time-to-event outcomes. Overall survival
(OS) and freedom from progression (FFP) were measured from the first day of RT. Estimates at specific
time points with associated 95% confidence intervals were reported. The exact logrank test was used
to assess the prognostic value of dichotomous variables on FFP. Hazard ratios and confidence intervals
were obtained from the Cox model. This was an “intention to treat” analysis and included all patients
who commenced treatment. Progression was defined as the first date on which the growth of new
disease was confirmed outside the radiation field by imaging or biopsy or there was regrowth or
increase in size of a previously known lesion within the radiation field. Patients with fluctuating small
volume lymphadenopathy of uncertain origin were considered to have disease progression only if
there was a progressive increase in nodal size, or if a biopsy confirmed the presence of lymphoma.
5. Conclusions
The results presented here confirm the efficacy of WFRT in stage III FL and suggest that it is
a potentially curative option in appropriately selected patients. The use of PET staging, rigorous
marrow evaluation and 3D conformal RT planning can produce results superior to those reported in
historic series. We suggest that the addition of targeted RT to systemic therapy in stage III FL should
be explored in future clinical trials. In the meantime, WFRT, with or without systemic therapy, could
be reasonably offered to patients with a long life expectancy and a desire for curative-intent treatment.
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